Stock Market Reviews

Read and share opinions on EDIT (Editas Medicine, Inc.) stock. Join MyTopStock.com to discover reviews, insights, and discussions from investors about this company's performance in the stock market.

Latest News

• Earnings Update: Editas Medicine, Inc. (NASDAQ:EDIT) Just Reported And Analysts Are Boosting Their Estimates
  Nov 13, 2025
• Editas Q3 Loss Narrower Than Expected, Revenues Increase Y/Y
  Nov 11, 2025
• Editas Medicine (EDIT) Reports Q3 Loss, Beats Revenue Estimates
  Nov 10, 2025
• Editas: Q3 Earnings Snapshot
  Nov 10, 2025
• Editas Medicine Announces Third Quarter 2025 Results and Business Updates
  Nov 10, 2025
• Editas Medicine Announces EDIT-401 Poster Presentation at the American Heart Association (AHA) Scientific Sessions 2025
  Nov 3, 2025
• Editas Medicine Reports In Vivo Proof-of-Concept Data for EDIT-401 at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress
  Oct 9, 2025
• Editas Medicine Announces EDIT-401 Oral Presentation at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress and Participation in Upcoming Investor Conferences
  Oct 6, 2025
• Institutions profited after Editas Medicine, Inc.'s (NASDAQ:EDIT) market cap rose US$47m last week but individual investors profited the most
  Sep 30, 2025
• Editas Medicine Inc. (EDIT) Confirms EDT-401 as Lead Vivo Program
  Sep 29, 2025
• Why Is Editas (EDIT) Down 16.9% Since Last Earnings Report?
  Sep 11, 2025
• Editas Nominates EDIT-401 as Lead In Vivo Therapy for High Cholesterol
  Sep 3, 2025
• Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate
  Sep 2, 2025
• Editas Medicine to Host Webinar Announcing Lead In Vivo Development Candidate
  Aug 28, 2025
• Editas Medicine to Participate in Upcoming Investor Conferences
  Aug 27, 2025